YOBINE- yohimbine hydrochloride injection, solution

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

Yohimbine Hydrochloride (UNII: NB2E1YP49F) (Yohimbine - UNII:2Y49VWD90Q)

Available from:

Akorn Animal Health, Inc.

INN (International Name):

Yohimbine Hydrochloride

Composition:

Yohimbine 2.0 mg in 1 mL

Administration route:

INTRAVENOUS

Prescription type:

PRESCRIPTION

Therapeutic indications:

Yohimbine should be used in dogs when it is desirable to reverse the effects of xylazine. Yohimbine has been used successfully to reverse the sedative effects of xylazine and to reverse the cardiac effects of xylazine such as arrhythmia and bradycardia when xylazine is administered alone.

Product summary:

20 mL multiple-dose vial. NDC 59399-115-20 NADA # 140-866, Approved by FDA

Authorization status:

New Animal Drug Application

Summary of Product characteristics

YOBINE- YOHIMBINE HYDROCHLORIDE INJECTION, SOLUTION
AKORN ANIMAL HEALTH, INC.
----------
YOBINE INJECTION
(yohimbine injection)
2.0 mg/mL
Xylazine Reversing Agent and Antidote
For Use in Dogs Only
CAUTION: Federal law restricts this drug to use by or on the order of
a licensed veterinarian.
DESCRIPTION:
Yobine
contains yohimbine with the chemical name 17 alpha-hydroxy-20
alpha-yohimban-16 beta-
carboxylic acid methyl ester. Yohimbine hydrochloride has a molecular
weight of 390.89, and the
molecular formula is C
H N O •HCl. The structural formula is:
Each mL contains: Yohimbine (as the hydrochloride) 2.0 mg,
methylparaben 0.9 mg, propylparaben 0.1
mg, citric acid 3.34 mg, and water for injection, pH adjusted with
sodium hydroxide.
INDICATIONS:
Yohimbine should be used in dogs when it is desirable to reverse the
effects of xylazine. Yohimbine
has been used successfully to reverse the sedative effects of xylazine
and to reverse the cardiac effects
of xylazine such as arrhythmia and bradycardia when xylazine is
administered alone.
DOSAGE AND ADMINISTRATION:
For intravenous injection. The usual dose is 0.5 mL/20 lb body weight
(0.05 mg/lb, or 0.11 mg/kg) to
reverse the sedative effects of xylazine. The carefully calculated
dose of yohimbine should be given
intravenously slowly.
WARNING:
Not for human use. This drug should not be administered to
food-producing animals.
PRECAUTIONS:
The safety of yohimbine in pregnant dogs or in dogs intended for
breeding has not been established.
Careful consideration should be given before administering to dogs
known to be epileptic or seizure
prone. The drug reverses the analgesic effects of xylazine as well as
the sedative effects. If the animal
was given xylazine for its analgesic properties, reversal may result
in return of normal pain perception.
®
®
21
26
2
3
ADVERSE REACTIONS:
Occasionally a dog that has been reversed will show signs of
apprehensiveness but this state quickly
subsides.
PHARMACOLOGY:
Yohimbine is an indolealkylamine alkaloid that acts primarily by
blocking c